

Francisco Leyva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3437284/publications.pdf>

Version: 2024-02-01

87
papers

5,331
citations

117571

34
h-index

88593

70
g-index

89
all docs

89
docs citations

89
times ranked

5230
citing authors

#	ARTICLE	IF	CITATIONS
1	Withdrawn as duplicate: Optimized Implementation of cardiac resynchronization therapy â€“ a call for action for referral and optimization of care. <i>Europace</i> , 2023, 25, .	0.7	2
2	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>Europace</i> , 2022, 24, 71-164.	0.7	370
3	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. <i>Europace</i> , 2022, 24, 165-172.	0.7	20
4	Greyzone myocardial fibrosis and ventricular arrhythmias in patients with a left ventricular ejection fraction >35%. <i>Europace</i> , 2022, 24, 31-39.	0.7	10
5	Myocardial Fibrosis Predicts Ventricular Arrhythmias and Sudden Death After Cardiac Electronic Device Implantation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 665-678.	1.2	30
6	Acute Hemodynamic Effects of Simultaneous and Sequential Multi-Point Pacing in Heart Failure Patients With an Expected Higher Rate of Sub-response to Cardiac Resynchronization Therapy: Results of Multicenter SYNSEQ Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	0
7	The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: insights from an <sc>individual patient data metaâ€analysis</sc> of <sc>COMPANION</sc> and <sc>CAREâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 1091-1093.	2.9	1
8	Implantable cardioverterâ€defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the â€real worldâ€™?. <i>European Journal of Heart Failure</i> , 2022, 24, 1223-1226.	2.9	0
9	Myocardial Fibrosis as a Predictor of Sudden Death in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 29-41.	1.2	61
10	Cardiac operations and interventions during the COVID-19 pandemic: a nationwide perspective. <i>Europace</i> , 2021, 23, 928-936.	0.7	33
11	Reply. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2158.	1.2	0
12	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>Europace</i> , 2021, 23, 1324-1342.	0.7	18
13	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2021, 42, 3427-3520.	1.0	899
14	First-Phase Left Ventricular Ejectionâ€Fraction. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2286-2287.	2.3	1
15	Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. <i>European Heart Journal</i> , 2020, 41, 1976-1986.	1.0	33
16	Effect of QRS area reduction and myocardial scar on the hemodynamic response to cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2020, 17, 2046-2055.	0.3	8
17	UK multicenter retrospective comparison of novel active versus conventional passive fixation coronary sinus leads. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2948-2953.	0.8	1
18	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>European Journal of Heart Failure</i> , 2020, 22, 2349-2369.	2.9	101

#	ARTICLE	IF	CITATIONS
19	Prognosis of incidental left bundle branch block. <i>Europace</i> , 2020, 22, 956-963.	0.7	6
20	Autofluorescence guided welding of heart tissue by laser pulse bursts at 1550 nm. <i>Biomedical Optics Express</i> , 2020, 11, 6271.	1.5	9
21	Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias. <i>Journal of the American Heart Association</i> , 2019, 8, e013539.	1.6	30
22	Out-of-hospital cardiac arrest due to idiopathic ventricular fibrillation in patients with normal electrocardiograms: results from a multicentre long-term registry. <i>Europace</i> , 2019, 21, 1670-1677.	0.7	34
23	Leadless Pacemaker Implantation in Hemodialysis Patients. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 162-170.	1.3	54
24	A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice. <i>Trials</i> , 2019, 20, 314.	0.7	6
25	Renal function and the long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 595-602.	0.5	5
26	Long-term outcomes of cardiac resynchronization therapy in adult congenital heart disease. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 573-580.	0.5	12
27	Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. <i>Heart</i> , 2019, 105, 1825-1831.	1.2	15
28	Sex-specific Differences in Survival and Heart Failure Hospitalization After Cardiac Resynchronization Therapy With or Without Defibrillation. <i>Journal of the American Heart Association</i> , 2019, 8, e013485.	1.6	11
29	Survival after cardiac resynchronization therapy: results from 50 084 implantations. <i>Europace</i> , 2019, 21, 754-762.	0.7	31
30	Risk Stratification Beyond Left Ventricular Ejection Fraction: Role of Cardiovascular Magnetic Resonance. , 2019, , 11-25.		0
31	Reference ranges for three-dimensional feature tracking cardiac magnetic resonance: comparison with two-dimensional methodology and relevance of age and gender. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 761-775.	0.7	42
32	Clinical outcomes after upgrading from pacemakers to cardiac resynchronization therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 290-298.	0.5	8
33	Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations. <i>European Journal of Heart Failure</i> , 2018, 20, 1472-1481.	2.9	39
34	Clinical outcomes and costs of cardiac revascularisation in England and New York state. <i>Open Heart</i> , 2018, 5, e000704.	0.9	4
35	Long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy. <i>Europace</i> , 2018, 20, 1804-1812.	0.7	33
36	Long-term Outcomes of Cardiac Resynchronization Therapy Using Apical Versus Nonapical Left Ventricular Pacing. <i>Journal of the American Heart Association</i> , 2018, 7, e008508.	1.6	12

#	ARTICLE	IF	CITATIONS
37	The Role of Cardiovascular Magnetic Resonance in Cardiac Resynchronization Therapy. <i>Heart Failure Clinics</i> , 2017, 13, 63-77.	1.0	12
38	Long-term requirement for pacemaker implantation after cardiac valve replacement surgery. <i>Heart Rhythm</i> , 2017, 14, 529-534.	0.3	48
39	Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy. <i>JACC: Heart Failure</i> , 2017, 5, 28-38.	1.9	262
40	Cardiac Resynchronization Therapy Using Quadripolar Versus Non-Quadripolar Left Ventricular Leads Programmed to Biventricular Pacing With Single-Site Left Ventricular Pacing: Impact on Survival and Heart Failure Hospitalization. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	45
41	Outcomes of Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1216-1227.	1.2	69
42	In vitro experimental results using autofluorescence spectroscopy to assess RF ablation of bovine heart. , 2017, , .		0
43	Mechanical effects of left ventricular midwall fibrosis in non-ischemic cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 1.	1.6	111
44	Effect of telemonitoring of cardiac implantable electronic devices on healthcare utilization: a meta-analysis of randomized controlled trials in patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 195-204.	2.9	100
45	Left ventricular lead position, mechanical activation, and myocardial scar in relation to left ventricular reverse remodeling and clinical outcomes after cardiac resynchronization therapy: A feature-tracking and contrast-enhanced cardiovascular magnetic resonance study. <i>Heart Rhythm</i> , 2016, 13, 481-489.	0.3	58
46	Haemodynamic effects of cardiac resynchronization therapy using single-vein, three-pole, multipoint left ventricular pacing in patients with ischaemic cardiomyopathy and a left ventricular free wall scar: the MAESTRO study. <i>Europace</i> , 2016, 18, 1227-1234.	0.7	25
47	The clinical outcome of cardiac resynchronization therapy in post-surgical valvular cardiomyopathy. <i>Europace</i> , 2016, 18, 732-738.	0.7	5
48	Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: the VALID-CRT risk score. <i>European Journal of Heart Failure</i> , 2015, 17, 717-724.	2.9	41
49	Implementation and reimbursement of remote monitoring for cardiac implantable electronic devices in Europe: a survey from the health economics committee of the European Heart Rhythm Association. <i>Europace</i> , 2015, 17, 814-818.	0.7	62
50	Myocardial strain measurement with feature-tracking cardiovascular magnetic resonance: normal values. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 871-881.	0.5	195
51	Improvement in Cardiac Energetics by Perhexiline in Heart Failure Due to Dilated Cardiomyopathy. <i>JACC: Heart Failure</i> , 2015, 3, 202-211.	1.9	77
52	National Institute for Health and Care Excellence 2014 guidance on cardiac implantable electronic devices: health economics reloaded. <i>Europace</i> , 2015, 17, 339-342.	0.7	13
53	Patients with Nonischemic Cardiomyopathy Requiring Cardiac Resynchronization Therapy Should Also Undergo Implantation of a Primary Prevention Defibrillator. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 461-468.	0.7	0
54	The Role of Cardiovascular Magnetic Resonance in Cardiac Resynchronization Therapy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 619-633.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Absolute survival after cardiac resynchronization therapy according to baseline QRS duration: A multinational 10-year experience. <i>American Heart Journal</i> , 2014, 167, 203-209.e1.	1.2	22
56	20 Years of Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1047-1058.	1.2	137
57	Feature-tracking cardiovascular magnetic resonance as a novel technique for the assessment of mechanical dyssynchrony. <i>International Journal of Cardiology</i> , 2014, 175, 120-125.	0.8	29
58	Interplay Between Right Ventricular Function and Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2153-2160.	1.2	74
59	Comparison of magnetic resonance feature tracking for longitudinal strain calculation with spatial modulation of magnetization imaging analysis. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013, 15, P123.	1.6	3
60	Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2013, 1, 500-507.	1.9	147
61	Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2013, 34, 1869-1874.	1.0	85
62	Letter by Taylor et al Regarding Article, "Myocardial Fibrosis as a Key Determinant of Left Ventricular Remodeling in Idiopathic Dilated Cardiomyopathy: A Contrast-Enhanced Cardiovascular Magnetic Study." <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, e78.	1.3	1
63	Left Ventricular Midwall Fibrosis as a Predictor of Mortality and Morbidity After Cardiac Resynchronization Therapy in Patients With Nonischemic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1659-1667.	1.2	169
64	Left ventricular reverse remodelling, long-term clinical outcome, and mode of death after cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2011, 13, 43-51.	2.9	59
65	Female Gender is Associated with a Better Outcome after Cardiac Resynchronization Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 82-88.	0.5	34
66	Fluoroscopic Left Ventricular Lead Position and the Long-Term Clinical Outcome of Cardiac Resynchronization Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 785-797.	0.5	24
67	Current and future role of cardiovascular magnetic resonance in cardiac resynchronization therapy. <i>Heart Failure Reviews</i> , 2011, 16, 251-262.	1.7	14
68	Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2011, 13, 29.	1.6	190
69	Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration: the RESPOND study. <i>Heart</i> , 2011, 97, 1041-1047.	1.2	43
70	Cardioverter-defibrillators: a cost or an investment?. <i>Europace</i> , 2011, 13, ii25-ii31.	0.7	10
71	Incidental cardiac findings on computed tomography imaging of the thorax. <i>BMC Research Notes</i> , 2010, 3, 326.	0.6	50
72	Cardiac resynchronization therapy guided by cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2010, 12, 64.	1.6	32

#	ARTICLE	IF	CITATIONS
73	Myocardial Infarction Does Not Preclude Electrical and Hemodynamic Benefits of Cardiac Resynchronization Therapy in Dyssynchronous Canine Hearts. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2010, 3, 361-368.	2.1	65
74	Effects of cardiac resynchronization therapy in patients unselected for mechanical dyssynchrony. <i>International Journal of Cardiology</i> , 2010, 143, 51-56.	0.8	10
75	Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. <i>European Heart Journal</i> , 2009, 30, 2749-2757.	1.0	48
76	What is treatment success in cardiac resynchronization therapy?. <i>Europace</i> , 2009, 11, v58-v65.	0.7	61
77	Short-Term Hemodynamic Effects of Cardiac Resynchronization Therapy in Patients With Heart Failure, a Narrow QRS Duration, and No Dyssynchrony. <i>Circulation</i> , 2009, 120, 1687-1694.	1.6	28
78	Radial dyssynchrony assessed by cardiovascular magnetic resonance in relation to left ventricular function, myocardial scarring and QRS duration in patients with heart failure. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2009, 11, 50.	1.6	34
79	Inclusion and exclusion criteria for CRT. <i>Heart Rhythm</i> , 2009, 6, 1235-1237.	0.3	3
80	Long-term effects of upgrading from right ventricular pacing to cardiac resynchronization therapy in patients with heart failure. <i>Europace</i> , 2008, 11, 495-501.	0.7	57
81	Late perforation of a defibrillator lead managed by percutaneous, intravenous extraction. <i>Europace</i> , 2008, 11, 255-257.	0.7	2
82	Is cardiac resynchronisation therapy proarrhythmic?. <i>Indian Pacing and Electrophysiology Journal</i> , 2008, 8, 268-80.	0.3	9
83	Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. <i>Europace</i> , 2007, 9, 1031-1037.	0.7	155
84	Intraventricular Dyssynchrony Predicts Mortality and Morbidity After Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2007, 50, 243-252.	1.2	138
85	Uric Acid and Survival in Chronic Heart Failure. <i>Circulation</i> , 2003, 107, 1991-1997.	1.6	532
86	New Insights Into the Progression of Aortic Stenosis: Implications for Secondary Prevention. <i>Circulation</i> , 2001, 103, E67.	1.6	1
87	Health Economics. , 0, , 419-435.		0